CytoCares (Shanghai) Inc. is a global, immune-oncology focused biotech company dedicated on the research & development of first-in-class therapeutics for cancer treatment.
Mission Statement: Continuous Innovation for Life-Changing Therapies to People in Need and Benefit the People.
The company has developed several proprietary immuno-oncology therapeutic platforms, including TriTETM, CCNKTM, and CCMφTM. The pipeline antibodies developed based on these platforms could stimulate or modulate immune cells to fight against cancer.
CytoCares is a pioneer in utilizing of “Two-Signal” system of T cell activation in the multi-specific antibody design and has expanded its expertise from hematologic malignancies to solid tumor. CytoCares’ CCNKTM platform is designed to harness the immune functions of NK cells in cancer treatment. Specially, new antibody formats capable of stimulating the antitumor activity of innate immune cells are now in development in CytoCares with the ultimate goal of long-lasting tumor control. Antibodies generated from CCMφTM platform are designed to target macrophage using the TAM (tumor associated macrophage) reprogramming strategies.
As the first batch of biopharmaceutical industrialization practitioners in China, Dr. Zhu has more than 20 years of industrial experience in genetically engineered protein and antibody technology. Dr. Zhu has participated in the development of 4 genetically engineered drugs successively, and has undertaken the Innovation Fund of Ministry of Science and Technology and new drug creation projects for many times.
Dr. Zhu, who received his Ph.D in genetics from Fudan University, is the founder of Suzhou Novoprotein Science and Technology Co., Ltd. He is also the Industrial Mentor of Fudan Master Program, the Visiting Professor of Shanghai Jiaotong University, the Council Member of the Genetics Society of China, and the Council Member of Vaccine Society.
PhD in biology from the Chinese University of Hong Kong.
20 years of direct experience with more than 10 different biologics in preclinical or clinical developments, including monoclonal antibodies, fc-fusion proteins, recombinant proteins, and pegylated proteins.
Areas of expertise include biologics early discovery, preclinical and clinical developments, and regulatory affairs.
Before joining CytoCares, Dr. Chen has served as senior scientist, Director of preclinical development, VP of R&D, and CTO in several biotech companies including CK Life Sciences (HK), Synermore Biologics (TW), and Bio-Cancer Treatment (BCT) Intl. Ltd.
Over 5-year experience of comprehensive operation management in biotech field, proficient in strategy making and business development, construction & optimization of business operation system, etc.
Over 10-year experience in PE & VC, familiar with investment in biotech, medical devices, IVD, and other healthcare and related fields, expert in business analysis & diagnosis.
Dr. Zeng received his Ph.D in genetics from Fudan University. He was an investment manager in Fosun Group, an Investment VP of Principle Capital, and a board director & vice general manager of of Genechem Co., Ltd.
No One Fights Alone